>> i think it should be higher. zillow. now it is higher. we have got ten seconds. >> i'm melissa lee. see you tomorrow at 5:00. don't go go anywhere. "mad money" with jim cramer starts right now. my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends, i'm trying to save you a little money. my job is not just to entertain but to educate and teach you. so call me 1-800-743-cnbc. where can we find the best growth right here right now? isn't that the be all and end all behind so much of we're looking for in the stock market? including today when the dow sank 21 points.

nasdaq advancedn .08%. it doesn't matter where we find growth. we always love it when we see it. tonight we hear from regeneron, not only has drugs that are making fortunes for shareholders right now, it also has drugs in the pipeline that could keep that growth going for many years to come. game changing medicines that are disrupting the market and crushing the competition. including many of the old line companies whose time seems spent. we can find growth in the oil patch where companies are putting up 30% production growth giving us increases which on days like today we walk away from. but when oil's up a buck, people smile on these. go crazy for the likes of pioneer, and eog. we love growth and rapidly expanding retailers and restaurants -- >> buy, buy, buy!

>> shares rallied $7.47. or starbucks which jumped 1.62 in the united kingdom. 5 cents mure for cappuccino produces a 1.3 billion rise in the company's capitalization. neither of these holds a candle to what michael kors the accessory chain accomplished today with an astounding 49% increase in profits. with same-store sales that soared 23%. anything north of 5% increase gets the growth managers, fund managers salivating. this was more than four times that. no wonder the buyers are willing to pay $79 for the stock, up $4.32 from the last sale. even though it sells 23 times next year's earnings, i think it's cheap. that's right, cheap, which means i think it's going higher. or there's the bull market in cell towers. which capitalized the wireless carry yes, sirs needing to reach more people with clearer signals. companies that you'll hear from tonight with astounding

year-over-year growth that keeps getting rewarded with the new highs, hey, listen, i've got a roof, welcome to it. . nothing gets investors more excited right now, though, than companies that harness mobile, social and the cloud. you have mobile and investors are interested. you have cloud and they're getting enthused. but if you have all three of them, the holy trinity of what's working right now. yes, they are partying down on that magical elixir that is growth! always wanted to do that. which brings me to the ultimate social mobile and cloud play on the horizon, the ipo of -- you fill it in. it's like one of those geico ads. yeah. okay? the mobile interactive website. i'm doing that. the mobile interactive website

taking the world by storm with almost 200 million active users up from half of that last year. as soon as next year, but certainly by 2015, has everything a growth accolade could possibly ask for. okay, i'm talking twitter, which is why i think it's going to be the hottest ipo since facebook, maybe even hotter than facebook. and that's what i want to talk about tonight. you see, i'm deathly afraid of another facebook deal happening here. what's another facebook mean to me? a deal where institutional investors who have done an immense amount of valuation work based on insider insights the rest of us don't have will be giving their final order indications tonight for the brokers for how much stock they like. i can tell you from people i talked to that many large institutions are simply saying to goldman sachs, the keeper of the books for the deal. look, i do a lot of commission business and i'll take every share i can get. i want 10% of the deal. i want to circle 10% of the deal. that level of demand for a stock is unprecedented. again, with the exception of facebook. the reasoning is twofold. first is a good one. these institutional investors

are very jazzed, excited about the possibility of owning shares in a company that's generated $620 million in revenue and super jazzed about the possibility of revenues increasing to about $1 billion the year after with double the profits. second, though, and this is what worries me about you. the big boys are betting that other less informed investors, people who use twitter and love it like me @jimcramer. people who don't know how to value the stock but figure how can you go wrong are going to come in and buy the stock from the professionals at much higher prices than they could hope to get on a purely valuation style of investing. in short, they want to fleece you. i want to stop that from happening. oh, sure, there'll be thick and thinners out there who believe in owning, not flipping and i'm okay with that. twitter does have a combination of users who love it and advertisers who thirst for it. a network created by users getting monetized and it doesn't need to be monetized much

overseas, but it will be. it makes tremendous sense to hold on and try to get more if you are a growth-aholic. i am thrilled for the big boys. i hope they get all the shares they want. what i worry about are the people who think there's no price that's not worth paying for twitter. there is a price where it's not worth owning, like i've been telling you, my limit on that valuation is $20 billion. that limit has to do with a combination of what i understand other companies would be willing to pay right now for the enterprise, coupled with an effective discount to facebook because of the smaller scale and lack of profitability. something facebook has in spades. more important, when it proves every single social mobile and cloud stock since it became public, if you have a stocken o the deal, go in on the underwriting, you made out like a ban did provided you sold it, but if you didn't and paid the opening price in the aftermarket, within a few months you lost money on every single one. in most cases including facebook you could buy the stock for

literally half of what they opened at or even less. that's right, not one of these stocks, yelp, zillow, linkedin, facebook, not to mention groupon were bargains for those who bought them in the market. they just weren't. they just weren't. they amounted to the equivalent of grand theft stock market. i want to point out in every single case except groupon, did get back to even and a remarkable ride to much higher prices as the blessings of the capabilities kicked in. and the analyst who has done the best preipo analysis of twitt t, is saying he feels confidemfort paying up to $40 for the stock. and his, the $28 and change amounts to $20 billion. he wants to pay, says you should be willing to pay more than that. but even peck, who is shrewd, and i did mock him initially. i don't like to see research of a company that's not yet public.

but he says his ultimate target is $50, 5-0. he believes it's twice of what i think you should pay for it. peck may be right and i may be right. twitter might get to $50 eventually. but will it reach 50 before visiting 25 or 23? will it go to 50 but shake you out at 20? worse, will it open at 50 so the upside's taken out from the start. no matter, what i care about is this. i'm giving you my blessing to pay $28 for twitter, far more than people were talking about paying for the company two weeks ago even as nothing new has happened to it. yes, a few weeks ago, people were laughing at me. they were laughing at me as if i were carrie saying i thought $20 billion made sense. the highest i heard back then when people were cackling was $15 billion. i didn't know a soul at $20 billion. now, again, with no new information, i'm suddenly the low man on the totem pole? come on, that's just wrong.

and worse, it's risky. here's my bottom line. i don't want you to take out the big boys at high prices. i don't want you to be the reason they make money on the twitter deal and you don't. i want the company's sales and earnings to be the reasons. so don't go nuts, take a deep breath. be conscious there is a price too high. and may you get as much twitter on the ipo as possible and as little after that. arnold in california. arnold. >> jim cramer, love your show. wonder eed how you felt about a and their management team. >> okay. david faber, my co-host along with carl quintanilla on "squawk on the street," he is chiding me. he's looking at -- there are three good a.c.t. words. here's the problem, the stock has been on fire, they're fixing their balance sheet, i think the order's going to be there. i'm not backing away even though we've got a big gain. i still like alu. mitch in california, mitch?

>> caller: hey, jim, my question's regarding lionsgate entertainment. the stock's been performing over 100% year-to-date and in the past month trading about 8% below the all-time high. i would like to know a good play going into earnings season this week as well as the new "hunger games" film. >> you've got to get through earnings before you get to "hunger games." i think "hunger games" is going to be good. i underestimated the first "hunger games." stock was at 16, went to 20 and proceeded to go to 30. i believe you have to wait until after the quarter and then it awaits you. are you atwitter about a social media ipo? and you know which one i mean. be prudent, don't be crazy. "mad money" will be right back. coming up, eye on the prize, cramer's tracking some of the most innovative biotechs on the street. >> next generation medical science is helping to drive regeneron to the top of the tape

today after reporting a blowout quarter. then, could acorda make a healthy investment? and later, power tower, your tablet, phone, watch and even your glasses, the more connected we become, the more rely on cell tower companies like sba communications. can an investment here connect you with cash? don't miss cramer's exclusive all coming up on "mad money." don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer #madtweets. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. (announcer) scottrade knows our clients trade

and invest their own way. with scottrade's smart text, i can quickly understand my charts, and spend more time trading. their quick trade bar lets my account follow me online so i can react in real-time. plus, my local scottrade office is there to help. because they know i don't trade like everybody. i trade like me. i'm with scottrade. (announcer) ranked highest in investor satisfaction with self-directed services by j.d. power and associates. at a ford dealer with a little q and a for fiona. tell me fiona, who's having a big tire event? your ford dealer. who has 11 major brands to choose from? your ford dealer. who's offering a rebate? your ford dealer. who has the low price tire guarantee, affording peace of mind to anyone who might be in the market for a new set of tires? your ford dealer. i'm beginning to sense a pattern.

get up to $140 in mail-in rebates when you buy four select tires with the ford service credit card. where'd you get that sweater vest? your ford dealer. ♪ ♪ so you can have a getaway from what you know. so you can be surprised by what you don't. get two times the points on travel and dining at restaurants from chase sapphire preferred. so you can taste something that wakes up your soul. chase sapphire preferred so you can.

if you don't have to own any of the totally en fuego biotech

stocks, i've got a speculative biotech stock that's been a laggard, i'm talking about acorda therapeutics, it's up almost 31% for the year. it's meager against this industry, but the stock has come down 16% since july, which is why it's so intriguing. it just reported what's known as a mixed quarter last thursday delivering a 16 cent earnings beat off a 23 cent basis even as the revenues came in slightly lower than expected. i don't care about that. it's not important. what really matters is the pipeline. and i think the quarter's pipeline holds a ton of promise. right now it's all about a drug called impura which helps patients regain some of their ability to walk. some people were worried because sales were basically flat versus the previous year. it's got multiple indications. it's being studied to see if it can restore walking abilities for stroke victims.

plus, acorda has a nasal spray. and on top of everything, they have an enormous early stage pipeline, including, perhaps, we have to talk about. something potentially i always have to caveat this, spinal cord injuries. let's take a closer look with dr. ron cohen, the founder and ceo of acorda therapeutics. welcome back to "mad money." >> thank you, jim. >> thank you, doc. i hesitate to spend that much time on impura because it's all known and you're a pipeline story that's backed by cash. do you think that's a fair characterization? >> absolutely. it's the engine, helps us go. and sales were up 13% over the same period last year. people were concerned because quarter over quarter, q2 to q3 was flat. and we narrowed our guidance, gave people $295 million to $305 million this year and that left

room for growth. >> i mentioned the epilepsy, the possibility of the stroke, these are big, big markets. spinal cord, which caught people's fancy? i know i was blown away by the slide show. >> i'm excited about it myself. if you think about it, two years ago when we first got -- we had just gotten ampyra to market to help people walk with m.s. we had one drug in clinical studies now we have six. so we made a lot of progress in two years. the one i think most people are focused on right now among many great ones is taking the same drug substance in ampyra and see if it can help people walk better who have had strokes. 7 million people living with it. >> of the markets that are left to tackle. >> right. >> right? >> that's a huge one. and about half of those people have ongoing walking disabilities. 800,000 new cases a year. and we showed in an initial trial some promise with this drug that seemed to actually improve walking speed in people

with post stroke. so we're going to talk to fda and hopefully if they agree, we'll start by the second quarter a new clinical study hopefully to help support approval. >> right. you go to tremendous lengths in the presentation to talk about the benchmarks you have to meet. in other words, you're setting up a study that basically pits -- well, doesn't pit, shows people with nothing that are just trying to get back -- this is about rehab. people rehabbing with your drug? >> so this is taking people who had a stroke anywhere from six months ago to 30 years from now. average of ten years, actually, after stroke. and whatever it is they're doing, it doesn't matter, we're going to bring in people who just have problems, maybe they're rehabbing, maybe not, we're going to give some of them this drug and some of them are going to get a placebo and we're not going to know which. and that's what we did in the first study and found that the people who got the drug did better than the people who got the placebo. >> it still could be a couple of years, right? >> yep. >> but it is an exciting new

world. >> it is very exciting. >> you're very understated in your presentations, which is good, no room for hype in this business. is there some sort of epidemic of epilepsy right now in this country? >> yes, there are about 2.3 million people with epilepsy. people in the field call it the hidden disease because most people with epilepsy, if they can, they don't tell people about it. you probably know a lot of people with epilepsy and don't know you know them. >> yes. they're trying to -- trying to keep it low key. >> correct. and some of these people, a lot of these people are not fully controlled on the medicines we have. they get breakthrough seizures, clusters, they'll get one seizure and a few hours later another one. these are dangerous and frightening. and only one medication that anyone can use at home without going to the emergency room. and it turns out you have to deliver it as a rectal gel. and most people aren't up for that. little kids can use it, their parents give it to them, so on. we've developed the same drug but in a nasal form.

you take a quick spray and it does, we think, the same thing. and we've announced today we've filed with the fda to ask for approval for that drug. and we could be on the market as early as next year some time. >> i think this is huge. the doctors i deal with on this particular issue adon't know. they're deathly afraid something bad's going to happen. they have nothing for these people. this could be it. >> well, this is a great rescue medication. >> right. that's what i'm talking about. something happens, there's people -- i just don't think people realize how big it is. >> it -- we think it's a very important indication. >> with the time left, i -- we have regeneron on later, i remember the initial regeneron, spinal cord injuries, everybody cares. anything within five years possible here? >> i founded the company based on my interest in spinal cord injury. we know how awful it is. we have a really exciting medication. we just started a clinical trial

in people with acute spinal cord injuries. and in preclinical studies, it showed a potential for rescuing spinal cord tissue so they preserve more function later. now, this trial's going to take a couple of years and hopefully we'll get some nice signal at the end of it. >> not a reason to buy acorda. a reason to follow. >> i agree. >> the other ones are reasons to buy. >> i would agree with that. >> that's dr. ron cohen president and ceo of acorda therapeutics. a remarkable presentation. some companies are trying to solve the big issues in this country in disease, acorda's one of them. stay with cramer. coming up -- 20/20. next generation medical science is helping to drive regeneron to the top of the tape today after reporting a blowout quarter. could the catalyst to come make this stock a healthy investment? don't miss cramer's exclusive. customer erin swenson ordered shoes from us online

but they didn't fit. customer's not happy, i'm not happy. sales go down, i'm not happy. merch comes back, i'm not happy. use ups. they make returns easy. unhappy customer becomes happy customer. then, repeat customer. easy returns, i'm happy. repeat customers, i'm happy. sales go up, i'm happy. i ordered another pair. i'm happy. (both) i'm happy. i'm happy. happy. happy. happy. happy. happy happy. i love logistics.

♪ [ male announcer ] more room in economy plus. more comfort, more of what you need. ♪ that's... built around you friendly. ♪

look at regeneron go. here's a biotech stock, one of the four horse men of the big pharma apocalypse that seems unstoppable to me. just reported this morning the company shot the lights out. truly stunning numbers. 52-cent earnings beat, 52-cent earnings beat off 1.88 basis. revenues that rose 39.6% year-over-year. biggest beat of the quarter, biggest beat of the year. what's more, we heard a lot of

chatter about regeneron's big block buster degeneration drug. which could potentially sell the turbo charged growth. what happens, once again the numbers are phenomenal. linked quarter with management raising their sales forecast and announcing they've asked the fda for approval for a new indication diabetic macula -- no matter how well the stock goes, it seems wall street can't get the collective head around the scale of the opportunity here. stock has given you a 65% gain since we last spoke to the ceo back in january, may be the best call in the history of "mad money" when i initially recommended regeneron trading at $5 back in 2005 after one of our earliest c.o. interviews. 5,995% gain, if you invested $1,000 in regeneron, it's $60,000. let's go back into the well with

the ceo of regeneron pharmaceuticals, learn more about the quarter and learn what's next for his business. withi welcome back to "mad money." >> thanks, jim. >> thanks for being here. welcome in on a big day. this was a beautiful play, this conference call because you started off with the 49% increase. but this diabetic edema, you're saying 570,000 people need and want this drug. >> well, it's a big opportunity. look, for us, regeneron, this was a big quarter and it's kind of rare in this business that every aspect of your business is working. >> right. >> we've got a true blockbuster, already done in the first nine months of the year, $1 billion in the u.s. selling the product well outside of the united states. >> you said it's in the early stages the term you used. early stages of this drug. >> just this week. we got pricing in france so they haven't even launched in france, which is a big opportunity. it's in the early stages outside

the united states. but a lot of opportunities to grow in the united states. >> okay. now you've got the name for it now. you're talking about a gigantic lowering of the bad cholesterol drug. others claim they're there. are you -- you on this call say you were ahead of them and this could be the next big regeneron drug. >> well, cholesterol lowering we know is an important part of any strategy to reduce cardiovascular disease. we think this new class of investigational drugs has the potential to add to that. there's lots of patients, people who have intolerants, people who can't get to go and there's room for competitors, we're going as fast as we can, but there's competition. just this past week, pfizer came out and said they're throwing their hat? . >> that's what i was going to ask you about. they said, come on, man, you like this regeneron, we're pfizer. >> we've got sanofi which is a great partner. so i think we're going to do pretty well. >> explain to people how you can

spend a lot of money in r & d like many other companies -- you're being reimbursed by a large company. >> sure. we have a very strong partnership where sanofi is spending a lot of money on our programs. but we said in this call, we're going to spend more of our own money. after we get this 20% -- we have this 20% responsibility once we have a positive phase 3. we're going to be spending more of our own money, that's going to go up, but we have a lot of good things to spend it on. you picked up the cholesterol drug early. >> i know, i can't take the darn stat statents. >> we should get you in one of our clinical trials. >> do it. >> i don't have any with me. however, there's another drug that you can get in on early in terms of investigational product. that's our drug to treat asthma, hopefully, and eczema. >> how can that do both? i thought it was a typo. >> right. these drugs are linked because they are part of a group of

diseases that are allergic diseases. you get asthma, eczema, nasal po poll -- we hope it's an opportunity, still investigational, a lot of risk, but we're very excited about it. >> your senior vice president used the phrase, it brought chills to me. we have seen a stabilization in your opponent, the share. was it 65, down to 48, why aren't you taking them -- those bad boys down to 40? why can't -- suddenly your drug, giving their drug away? >> well, no, their drug is a lot cheap eer and it's used awful label and there are structural changes coming in compound legislation. >> meaning that the government may not really like that kind of split up of the vial. >> regeneron's view is we're in

favor of choice. while patients should have lots of choices which is good to have a choice, it's good to have a choice, we think there should only be one quality standard. lots of drugs but only one quality standard. we think that's what the new law may accomplish and we're looking forward to that. >> okay. but we have seen instances where you break open the vial where there's been horrible -- there's been deaths. >> well, there's been deaths when people have injected drugs that have compounded. there has been blindness. this is why we need one quality standard. we need the fda to regulate this and that's what i think the new compounding legislation if it gets passed will actually do and it'll make things safer. >> now, just circle back, it's pertinent now. the diabetic, you're saying that's ready. that's one of the things -- you're saying they're just waiting. you're ready to go the moment that thing -- >> we are ready to go but we still have to go through the approval process. we've submitted -- >> what are those people taking right now? >> they're using lucentis, it's

ahead of us. there's some opportunity out there for people to get treated. we think our drug could be good, but we have to go through the review process with the fda. it's an exciting opportunity. >> we've got allergies, cholesterol, diabetic macular, and we have eylea, a lot happening. >> we have an enormous talent in the labs and he and his research team have come up with different opportunities for us, we've got 13 different products in clinical development and a whole bunch more moving forward which we haven't talked with you about. >> excellent. well, i know we're going to in the future. go and listen to this conference call. you will know why i am still excited even at $300 a share. stay with cramer.

tomorrow, kick off the trading day with "squawk on the street." live from post 9:00 at the nyse. >> they have a plan, it just happens to be a long-term plan. very long. >> 400 years? >> yeah, i think 400 year plan. >> it all starts at 9:00 a.m. eastern. bny mellon combines investment management & investment servicing,

giving us unique insights which help us attract the industry's brightest minds who create powerful strategies for a country's investments which are used to build new schools to build more bright minds. invested in the world. bny mellon.

it is time -- it is time for the "lightning round" on cramer's "mad money." say the name of the stock, i tell you whether to buy or sell. play until this sound -- and then the "lightning round" is over. are you ready ske-daddy. time for the "lightning round" on cramer's "mad money." gil in florida. gil? >> caller: jim, yeah, i know you're a delta guy, but what about u.s. airway stocks. >> if it gets through a deal with the justice department, that stock is a -- >> buy, buy, buy -- >> and probably goes right to 30. i don't know if the justice department is that savvy to realize that u.s. airways amr deal, wow. that stock doubles if we get it done. let's go to joe in georgia. joe? yo, joe? >> caller: hi, this is joe from georgia. first-time caller.

what's the status on this? >> i think you've had a very big run in rambus, ring the register, in the end, it's not exciting technology from semiconductors. jared in texas. >> caller: hi, this is jared here in texas. we want to say boo-yah, jimmy. >> boo-yah right back at you. obviously you're from dallas, not houston or else you wouldn't be so upbeat. what's up? >> caller: tell me something good about matador resources. >> it's interesting, but you're passing up on eog if you do matador and i'd rather see you in eog. denise in pennsylvania. denise? >> caller: hey, boo-yah, jim. >> boo-yah, denise. >> caller: i want to start off, of course, by thanking you and your staff. you guys are incredible. you've taught me so much. >> we have an unbelievable staff that make me look good every single day which, believe me requires a lot of work. what's up? >> caller: okay, my question is on petrobras.

with the fuel prices in order to control their inflation, that, of course, has a negative impact on the revenues, is it still a good investment? >> i've liked it for a buck and i reiterate i like it. that stock is in a slump otherwise it'd be at 20. if people are worried about government intervention, i think pbr is fine. i need to go to joel in iowa. joel? >> caller: boo-yah, jim. >> boo-yah. >> caller: this is joel in waterloo and i'm curious about alcoa. they've been up in the price and a good report. >> that stock has been creeping up step by step inch by inch, slowly alcoa goes higher. i think three initiatives, one, taking on the lme which i believe is not a good enterprise, two, cutting the costs dramatically, including cutting factories in italy and spain, and three, being linked to aerospace all to me saying -- >> buy, buy, buy!

next stock $12. >> jake in new york, jake! jake, what's up? >> caller: boo-yah, jim cramer, from upstate new york. >> caller: my stock is merck. >> all right. here's the problem with merck. merck is stymied, old pharma, don't know necessarily what it's doing. we are going to be definitive in the -- >> don't buy, don't buy. >> and i'm ashamed to say that because i want merck to do well, but i don't think it's got the gusto. let's go to matt in maryland, please, matt? >> caller: hi, jim, how about a marine corps boo-rah. >> don't forget, veterans day coming up, big show here. how can i help? >> caller: i'm calling about conocophillips. wondering what your thinking is now the time to buy with wti crude? >> i think conocophillips is a terrific investment. i do want to buy. one more. i'm going to mike, mike, mike in illinois. mike?

>> caller: jim, i've got a small position in uri, i initiated it in the low 30s. looking at the numbers going forward, is it still a hold? >> we don't care where the stock came from, we care where it's going to. no one got hurt taking a profit, you got a double and that said, i think it told a good story last week and the stock goes to 80 a share before i think it's too expensive. and that, ladies and gentlemen, is the conclusion of the "lightning round." >> the "lightning round" is sponsored by td ameritrade. coming up -- power tower. your tablet, your phone, your watch and even your glasses. the more connected we become, the more we rely on cell tower companies like sba communications. can an investment here connect you with cash. don't miss cramer's exclusive. w. it told him what was happening on the trading floor in real time. ♪ the shell brought him great fame. ♪ but then, one day, he noticed

that everybody could have a magic seashell. [ indistinct talking ] [ male announcer ] right there in their trading platform. ♪ [ indistinct talking continues ] [ male announcer ] so the magic shell went back to being a...shell. get live squawks right in your trading platform with think or swim from td ameritrade. that's mine. ♪ that's mine. that's mine. ♪ come on, kyle. ♪ [ horn honks ] that's mine...kyle. [ male announcer ] revenge is best served with 272 horses. get the best offers of the season now. lease this 2014 ats for around $299 a month with premium care maintenance included. ♪ that's a good thing, but it doesn't cover everything. only about 80% of your part b medical expenses. the rest is up to you. so consider an aarp medicare supplement insurance plan,

insured by unitedhealthcare insurance company. like all standardized medicare supplement insurance plans, they could save you in out-of-pocket medical costs. call today to request a free decision guide. with these types of plans, you'll be able to visit any doctor or hospital that accepts medicare patients... plus, there are no networks, and virtually no referrals needed. join the millions who have already enrolled in the only medicare supplement insurance plans endorsed by aarp... and provided by unitedhealthcare insurance company, which has over 30 years of experience behind it. with all the good years ahead, look for the experience and commitment to go the distance with you. call now to request your free decision guide.

there are times when it could be hard to find a bull market in anything that's easy to get your head around. this is not one of those moments. right now we've got a red hot bull market and tower stocks.

the backbone of mobile networks around the globe. these towers are everywhere. you probably see at least one on your daily commute. and this one is one of the things in your daily life where you see it and do the homework and realize, yes, the group even with their like funny little pine trees that are really towers is extremely viable. last month i told you about there's been this gigantic spade of acquisitions in the tower space. but the industry basically coalescing into what some say is the slap happy oligopoly. and it's the last one, which in many ways may be the best we want to talk about tonight. sbac has over 17,000 towers spread across the united states, canada, latin america, making it half the size of crown castle. it has terrific economics. once you build a tower, you can sell antenna space on that site to three or four different clients. and the incremental margins for

additional attentha array. reported they hit it out of the park. street was looking for a 15-cent loss. revenues came in higher than expected rising 39.2% year-over-year, management gave upside guidance for the next year, no wonder the stock jumped 3.86% today in a growth love fest. giving you about a 250% gain. since we last spoke to the ceo way back in october 2009. it's up around 80% since we highlighted it in april last year. the stock keeps chugging higher and higher, more room to run. don't take it from me. let's check in with the president and ceo of sba communications, hear more about the quarter and where his company is headed. welcome back to "mad money." >> hello, jim. thanks for having me. >> sir, i want to start. there are very few companies that point-blank say it, but you did. you see growth for and i quote the next several years. what gives you that level of confidence? >> well, jim, we are in an industry that really thrives on

the consumer demand for wireless. and our markets we are in a situation where the carriers our customers are investing heavily to provide faster speeds, higher quality and better wireless experiences. and the only way to provide t t that, well, there's one of two ways, actually, you can have more spectrum or provide more equipment. as i think you know, wireless spectrum is extremely limited and finite. what our customers are doing is satisfying those demands through additional equipment and that's where sba fits in. >> now, you talk about something i want our viewers to understand, organic growth and portfolio growth. can you explain the difference and why you've got both going? >> yes. organic growth is the business that we add on our existing assets. that's our most profitable business, it's the business that requires virtually no additional capital to capture and has the greatest and most positive impact on margins. now, we also grow through

growing our asset base through buying and building towers. and we have a history of executing well on the portfolio growth side. we've been in the business a long time. we think we've developed a good nose for good-quality tower ax sets. we can create good value for our shareholders by growing our portfolio with good assets that once they're in the portfolio, enjoy strong organic growth. >> are there still good properties for you to buy? and how do you compete against american tower and crown? they're very aggressive too. >> they are. thankfully it's a big world out there and there's a lot of tower opportunities and a lot of assets that have traded hands over the last couple of years and i think will continue to trade hands. we're an entrepreneurial company. we will get our fair share. we expanded into latin america in the last several years just so that we would have additional opportunities to add assets to our portfolio and not be limited to the united states, which is a

very good market, but there's also other good markets out there that if we invest right, we can create good shareholder value. >> very early on in your statements, you talk about how t-mobile and sprint, we know from dan hesse who runs sprint are mandating, mandating they need more towers. what does that mean? what is behind that incredible thirst by those two companies who aren't as big as verizon and at&t. spending like mad to put up more towers. >> well, all carriers in the u.s. today and shortly around the world are going to be racing to 4g, that's the fourth generation technology of wireless services. it's more commonly called lte. and both sprint and t-mobile are racing to try and close the gap a little bit on the network quality issues that exist between them and at&t and verizon today. they're both very focused, very serious about improving their networks and sba's been a beneficiary of that. >> final little, real estate

investment trust. i know you've gotten that operating loss balance. would you consider converting to a reit prior to utilizing the nols or does that not make sense? >> you know, jim, ultimately we will be a reit. i think it's going to be the best vehicle to create long-term shareholder value. but my view on what really is necessary to optimize your status as a reit and that investor base is to pay a healthy dividend. today we're compounding the cash inside our company at a 20% rate and the shareholders that we have today, they like that, they like the fact that we are focused on portfolio growth and potentially stock repurchases. but at some point in the future, you know, dividend will make sense for us and so will reit status. but probably it's not an imminent election for us. >> i don't blame you, most companies would be jealous of your level of growth. the last thing you want to do is put money back. president and ceo of sba communications, thank you so much for coming on the show. >> jim, thanks for having me. >> guys, this is one of the

great bull markets of this moment, okay. you know it, you know from your phone. you want more antenna, i want more roam, i want better reception. it's this company, amt and it's crown. and they are all good but sba may have the most to go. stay with cramer. this veterans day, "mad money" honors those who defend our country's freedoms by helping their financial futures. if you or someone in your family is proudly serve or has served in america's armed forces, we invite you to join our live studio audience this friday for "mad money" invest in america salute to the troops. for tickets go to madmoney.cnbc.com.

i'm jim cramer and welcome to my world. >> one man -- one mission. >> i want to make you money. >> eight years. >> you need to get in the game! >> tens of thousands of miles traveled. >> this new black gold rush is just getting started. it's the sound of american industry roaring back to life. >> hundreds of ceos. >> my life story can be your life story. >> thousands of callers. >> boo-yah, jimbo. >> millions of your e-mails and tweets. "mad money" thanks cramerica for being with us for over 2,000 episodes.

you can judge a great market by the quality of its secondary offerings and the reactions to them. those offerings by companies, they dump stock. take two deals we had last week, yelp and western digital which each sold shares to $67 and both have run to $71. in no time flat to get those four. don't you want it? i'm a huge fan of yelp. the company may have had the most powerful of all the recent offerings. now that you can write reviews on the go. yelp is expanding worldwide in order to box out potential competitors who might have the idea of going in against them including the googles and facebook. something i love because it reminds me of amazon during the old days. building out the international business like any great international story, it's getting terrific traction. i love a model like yelp which is like twitter, built on user content that don't cost nothing. yelpers write review and companies need reviewing and they want terrific place ads near those reviews.

it's a circle here. i know from my co-ownership down the block from the summit that yelp reviews can -- listen if you're in the service business -- make or break your business. it is that powerful. it is, indeed, a global online yellow pages with commentary. the opportunity so great for yelp that i told you the company would do a secondary offering to raise capital after reporting an excellent quarter. i said you should wait until the secondary drives down and buy some. 270% increase in earnings, but then the company also filed a secondary and people ran from the stock like it was toxic. got bad reviews on yelp. but that's where the opportunity came in. and the $67 pricing made for a fantastic buy, one i think will stand up over time. it's already looking like a steal as the stock rallied to 71. how about this offering by western digital. this company bought hitachi

global storages in exchange for 25 million shares for western digital a year ago. since then, it's rallied and down 80% in part because of the acquisition of stek to expand beyond the trishld hard drive business. so hitachi decided to ring the register on 10.9 billion of their shares. made sense. secondary price deliciously in the hole, $6 below that level. again, a fabulous opportunity, western digital was trading around eight times earnings at that price, the company's doing much better than it used to be because of the higher margin change. and bingo, you made the floor. 3.75 million shares to help finance acquisitions and drilling in the eagle ford which we like and the utica. adjusted net income when it reported monday night, an amazing 41% increase as the company shifted dramatically and successfully away from the glutted natural gas market.

i'm sure people were disappointed in the carrizo stock. but that company's on a major growth path and i love equity financing versus expensive debt which is what the wildcatters still have to pay to get funding. i say if oil stabilizes around here, which i think it will, this one could be as successful as western digital and yelp. and you'll be able to get carrizo at a terrific price, much lower than you see on your screen right now. yes, i spy a third successful secondary right in the offing. stay with cramer. mad about "mad money"? immerse yourself into cramer's world while you watch the show with zeebox. on your phone, tablet or on the web, get sneak peeks. go behind the scenes and join the conversation. download the free app today for the ultimate cramerican adventure. customer erin swenson ordered shoes from us online

but they didn't fit. customer's not happy, i'm not happy. sales go down, i'm not happy. merch comes back, i'm not happy. use ups. they make returns easy. unhappy customer becomes happy customer. then, repeat customer. easy returns, i'm happy. repeat customers, i'm happy. sales go up, i'm happy. i ordered another pair. i'm happy. (both) i'm happy. i'm happy. happy. happy. happy. happy. happy happy. i love logistics.

♪ ♪ so you can get out of your element. so you can explore a new frontier and a different discipline. get two times the points on travel and dining at restaurants from chase sapphire preferred. so you can be inspired by great food once again. chase sapphire preferred. so you can. people have been angry @jimcramer on twitter that i've been saying tesla's the stock. if there's one glitch, if something goes wrong, if they don't make as many cars, the stock's going to go down. there was one glitch, they didn't make as many cars to sell and it's going down. hey, that's why i don't like to

recommend those stocks, i like to acknowledge they are, indeed, colts f cults. it's election night in america. polls have just closed in virginia. did the obama care debacle hurt democrat terry mcauliffe or did a libertarian candidate steal votes from republican ken cuccinelli. we will get a live report from virginia in just a moment. chris christie expects to be re-elected in a landslide in new jersey. will we be seeing him again on election night in 2016. new york city moving left, i mean far left, with a new mayor that wants to tax everything that moves. and is president obama now lying about his original lie? the president tries to change what he's been saying for the past few years